Kelleher Financial Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.17M | Buy |
17,214
+8,604
| +100% | +$1.13M | 0.31% | 63 |
|
|
2026
Q1 | $1.2M | Buy |
8,610
+24
| +0.3% | +$3.36K | 0.3% | 59 |
|
|
2025
Q4 | $1.05M | Buy |
8,586
+8,168
| +1,954% | +$993K | 0.24% | 62 |
|
|
2025
Q3 | $46.4K | Sell |
418
-7,662
| -95% | -$871K | 0.01% | 350 |
|
|
2025
Q2 | $896K | Buy |
8,080
+18
| +0.2% | +$1.92K | 0.31% | 46 |
|
|
2025
Q1 | $903K | Buy |
8,062
+33
| +0.4% | +$3.4K | 0.36% | 45 |
|
|
2024
Q4 | $742K | Sell |
8,029
-215
| -3% | -$19.4K | 0.28% | 48 |
|
|
2024
Q3 | $691K | Buy |
8,244
+138
| +2% | +$10.5K | 0.26% | 54 |
|
|
2024
Q2 | $556K | Buy |
8,106
+475
| +6% | +$31.7K | 0.23% | 60 |
|
|
2024
Q1 | $559K | Buy |
7,631
+65
| +0.9% | +$5K | 0.23% | 61 |
|
|
2023
Q4 | $613K | Sell |
7,566
-110
| -1% | -$8.56K | 0.29% | 52 |
|
|
2023
Q3 | $575K | Sell |
7,676
-348
| -4% | -$26.8K | 0.29% | 51 |
|
|
2023
Q2 | $619K | Buy |
8,024
+38
| +0.5% | +$3.03K | 0.36% | 49 |
|
|
2023
Q1 | $663K | Buy |
7,986
+54
| +0.7% | +$4.47K | 0.44% | 44 |
|
|
2022
Q4 | $681K | Buy |
7,932
+32
| +0.4% | +$2.53K | 0.51% | 37 |
|
|
2022
Q3 | $487K | Buy |
7,900
+1,650
| +26% | +$104K | 0.35% | 57 |
|
|
2022
Q2 | $386K | Buy |
6,250
+94
| +2% | +$5.82K | 0.17% | 90 |
|
|
2022
Q1 | $366K | Buy |
6,156
+300
| +5% | +$19.2K | 0.2% | 84 |
|
|
2021
Q4 | $425K | Sell |
5,856
-3,796
| -39% | -$261K | 0.23% | 75 |
|
|
2021
Q3 | $674K | Buy |
9,652
+4,862
| +102% | +$342K | 0.3% | 80 |
|
|
2021
Q2 | $330K | Buy |
4,790
+22
| +0.5% | +$1.47K | 0.19% | 88 |
|
|
2021
Q1 | $308K | Buy |
4,768
+107
| +2% | +$6.9K | 0.2% | 83 |
|
|
2020
Q4 | $272K | Buy |
4,661
+14
| +0.3% | +$845 | 0.2% | 82 |
|
|
2020
Q3 | $294K | Buy |
4,647
+12
| +0.3% | +$832 | 0.24% | 72 |
|
|
2020
Q2 | $357K | Buy |
4,635
+11
| +0.2% | +$843 | 0.34% | 66 |
|
|
2020
Q1 | $346K | Sell |
4,624
-299
| -6% | -$20.7K | 0.41% | 55 |
|
|
2019
Q4 | $320K | Sell |
4,923
-108
| -2% | -$7.03K | 0.32% | 67 |
|
|
2019
Q3 | $319K | Buy |
5,031
+747
| +17% | +$48.8K | 0.39% | 62 |
|
|
2019
Q2 | $289K | Buy |
+4,284
| New | +$282K | 0.36% | 68 |
|
|
2018
Q4 | $261K | Sell |
4,165
-243
| -6% | -$17K | 0.42% | 65 |
|
|
2018
Q3 | $340K | Buy |
4,408
+31
| +0.7% | +$2.34K | 0.44% | 60 |
|
|
2018
Q2 | $310K | Buy |
4,377
+153
| +4% | +$10.8K | 0.44% | 63 |
|
|
2018
Q1 | $318K | Sell |
4,224
-24
| -0.6% | -$1.91K | 0.43% | 60 |
|
|
2017
Q4 | $304K | Sell |
4,248
-75
| -2% | -$5.7K | 0.48% | 61 |
|
|
2017
Q3 | $350K | Buy |
4,323
+2
| +0% | +$153 | 0.74% | 49 |
|
|
2017
Q2 | $306K | Sell |
4,321
-43
| -1% | -$2.86K | 0.59% | 58 |
|
|
2017
Q1 | $296K | Buy |
4,364
+599
| +16% | +$42.1K | 0.63% | 54 |
|
|
2016
Q4 | $270K | Buy |
3,765
+107
| +3% | +$7.95K | 0.15% | 109 |
|
|
2016
Q3 | $289K | Hold |
3,658
| – | – | 0.16% | 103 |
|
|
2016
Q2 | $305K | Sell |
3,658
-958
| -21% | -$85K | 0.19% | 97 |
|
|
2016
Q1 | $424K | Buy |
+4,616
| New | +$416K | 0.23% | 91 |
|
Other funds holding GILD
Kelleher Financial Advisors's GILD Position: Q2 2026 in Review
Kelleher Financial Advisors increased its Gilead Sciences (GILD) stake by 100% in Q2 2026, buying an estimated $1.13M and bringing the position to 17,214 shares worth $2.17M. The position accounts for 0.31% of the portfolio, ranked #63.
Kelleher Financial Advisors first reported a position in GILD in Q1 2016 and has held it in 41 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Kelleher Financial Advisors held 17,214 shares of Gilead Sciences worth $2.17M as of Q2 2026.
- Kelleher Financial Advisors bought 8,604 Gilead Sciences shares in Q2 2026, an estimated $1.13M.
- Gilead Sciences made up 0.31% of Kelleher Financial Advisors's portfolio in Q2 2026, its #63 holding.
- Kelleher Financial Advisors first reported a position in Gilead Sciences in Q1 2016 and has held it in 41 quarters since.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Kelleher Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.